================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 20, 2004 MEDICIS PHARMACEUTICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-18443 52-1574808 (State or Other (Commission File Number) (IRS Employer Jurisdiction of Incorporation) Identification No.) 8125 North Hayden Road Scottsdale, Arizona 85258-2463 (Address of Principal (Zip Code) Executive Offices) Registrant's telephone number, including area code: (602) 808-8800 N/A ------------------------------------------------------ (Former Name or Former Address, if Changed Since Last Report) ================================================================================ Item 5. Other Events and Regulation FD Disclosure On April 20, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had entered into an asset purchase agreement, license agreement and securities purchase agreement with BioMarin Pharmaceutical, Inc. A copy of the Company's press release is attached hereto as Exhibit 99.1. Item 7. Financial Statements and Exhibits (a) Financial Statements of Business Acquired. Not Applicable. (b) Pro Forma Financial Information. Not Applicable. (c) Exhibits. 99.1 Copy of press release, dated April 20, 2004, issued by Medicis Pharmaceutical Corporation SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. MEDICIS PHARMACEUTICAL CORPORATION (Registrant) Date: April 21, 2004 /s/ Mark A. Prygocki, Sr. ---------------------------------------- Name: Mark A. Prygocki, Sr. Title: Executive Vice President, Chief Financial Officer, Corporate Secretary and Treasurer EXHIBIT INDEX EXHIBIT NUMBER DESCRIPTION - ------ ----------- 99.1 Copy of press release, dated April 20, 2004, issued by Medicis Pharmaceutical Corporation